Amir Khandani, MD
Amir Khandani, MD
Specialty: Radiology
Program: Diagnostic Imaging and Interventional Radiology
Language(s): English
-
Publications
- Oldan JD, Schroeder JA, Khandani A, Collins H, Pope J, Huynh R, Ivanovic M, Rowe SP. Real-Time Imaging of 177Lu-Labeled Radiopharmaceutical Infusions with a Portable γ-Camera: Pilot Trial Results. J Nucl Med Technol. 2026 Mar.54(1):55-58. Pubmedid: 41529930.
- Oldan JD, Schroeder JA, Hoffman-Censits J, Rathmell WK, Milowsky MI, Solnes LB, Nimmagadda S, Gorin MA, Khandani AH, Rowe SP. PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers. PET Clin. 2024 Apr.19(2):197-206. Pubmedid: 38199916.
- Muhleman MA, Fahim A, Benefield T, Oldan JD, Khandani AH. One institutions' experience with a true standard 15 mCi dose of I-131 for the treatment of Graves' disease. Nucl Med Commun. 2023 Jan.44(1):49-55. Pubmedid: 36514928.
- Oldan JD, Femi-Abodunde AD, Muhleman MA, Khandani AH. Rubidium Uptake in Chest Tumors on PET/CT. World J Nucl Med. 2022 Mar.21(1):18-27. Pubmedid: 35502285. Pmcid: PMC9056130.
- Oldan JD, Khandani AH. Incidental renal masses on SPECT/CT and PET/CT. Am J Nucl Med Mol Imaging. 2022 Jun.12(3):81-85. Pubmedid: 35874298. Pmcid: PMC9301087.
- Voorhees TJ, Zhao B, Oldan J, Hucks G, Khandani A, Dittus C, Smith J, Morrison JK, Cheng CJ, Ivanova A, Park S, Shea TC, Beaven AW, Dotti G, Serody J, Savoldo B, Grover N. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Adv. 2022 Feb.6(4):1255-1263. Pubmedid: 34666347. Pmcid: PMC8864661.
- Muhleman MA, Oldan JD, Khandani AH. Incidental findings on a Tc99m-SESTAMIBI parathyroid scan post COVID-19 vaccination. Am J Nucl Med Mol Imaging. 2022 Apr.12(2):71-73. Pubmedid: 35535123. Pmcid: PMC9077171.
- Michael J, Khandani AH, Basak R, Tan HJ, Royce TJ, Wallen E, Whang Y, Rose TL, Milowsky M, Bjurlin MA. Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer. Urology. 2021 Sep.155:192-198. Pubmedid: 33516829.
- Kim SI, Szeto AH, Morgan KP, Brower B, Dunn MW, Khandani AH, Godley PA, Rose TL, Basch EM, Milowsky MI, Whang YE, Crona DJ. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. PLoS One. 2021 Jun.16(6):e0253021. Pubmedid: 34153052. Pmcid: PMC8216516.
- McCloskey H, Jacobs J, Zambrano I, Moore T, Khandani AH, Bjurlin MA. Salvage Pelvic Lymph Node Dissection and Current State of Imaging for Recurrent Prostate Cancer: Does a Standard Exist?. Curr Urol Rep. 2020 Nov.21(12):62. Pubmedid: 33159608.
- Rodriguez JD, Kirk D, Benefield T, Maygarden SJ, Pou K, Kim LT, Hackman TG, Khandani AH. Outcome of radioiodine therapy in thyroid cancer patients with recent contrasted computed tomography. Nucl Med Commun. 2020 Mar.41(3):228-234. Pubmedid: 31895755.
- Oldan JD, Glaubiger SA, Khandani AH, Jewells VL. Detectable size of melanoma metastases to brain on PET/CT. Ann Nucl Med. 2020 Aug.34(8):545-548. Pubmedid: 32451886.
- Khandani AH, Commander CW, Desai H, Oldan JD, Wong TZ, Benefield T, Ivanovic M. Visual and semiquantitative analysis of 82Rb uptake in malignant tumors on PET/CT: first systematic analysis. Nucl Med Commun. 2019 May.40(5):532-538. Pubmedid: 30920430.
- Oldan JD, Miller SM, Barnes A, Khandani AH. Trapping of 18F-Fluciclovine (FACBC) in Superior Sagittal Sinus. Clin Nucl Med. 2019 Jan.44(1):48-49. Pubmedid: 30394925.
- Yin Q, Hung SC, Rathmell WK, Shen L, Wang L, Lin W, Fielding JR, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D. Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma. Clin Radiol. 2018 Sep.73(9):782-791. Pubmedid: 29801658. Pmcid: PMC6078810.
- Oldan JD, Khandani AH, Fielding JR, Jones EL, Gehrig PA, Sills TM, Roy P, Lin W. Quantitative accuracy of positron emission tomography/magnetic resonance and positron emission tomography/computed tomography for cervical cancer. World J Nucl Med. 2018 Oct.17(4):213-218. Pubmedid: 30505216. Pmcid: PMC6216731.
- Oldan JD, Shin HW, Khandani AH, Zamora C, Benefield T, Jewells V. Subsequent experience in hybrid PET-MRI for evaluation of refractory focal onset epilepsy. Seizure. 2018 Oct.61:128-134. Pubmedid: 30138825.
- Khandani AH, Bravo IM, Patel PS, Ivanovic M, Kirk D. Frequency of high blood glucose prior to FDG PET. Abdom Radiol (NY). 2017 May.42(5):1583-1585. Pubmedid: 27999884.
- Yin Q, Hung SC, Wang L, Lin W, Fielding JR, Rathmell WK, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D. Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study. Sci Rep. 2017 Mar.7:43356. Pubmedid: 28256615. Pmcid: PMC5335708.
- Zagar TM, Kaidar-Person O, Tang X, Jones EE, Matney J, Das SK, Green RL, Sheikh A, Khandani AH, McCartney WH, Oldan JD, Wong TZ, Marks LB. Utility of Deep Inspiration Breath Hold for Left-Sided Breast Radiation Therapy in Preventing Early Cardiac Perfusion Defects: A Prospective Study. Int J Radiat Oncol Biol Phys. 2017 Apr.97(5):903-909. Pubmedid: 28333011.
- Brooks SA, Khandani AH, Fielding JR, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, Rathmell WK. Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. Clin Cancer Res. 2016 Jun.22(12):2950-2959. Pubmedid: 26787754. Pmcid: PMC4911278.
- Reeder-Hayes KE, Freburger J, Feaganes J, Peacock Hinton S, Henderson LM, Massing M, Schenck AP, Stearns SC, Carpenter WR, Chen RC, Khandani AH. Comparative effectiveness of follow-up imaging approaches in pancreatic cancer. J Comp Eff Res. 2014 Sep.3(5):491-502. Pubmedid: 25350801.
- VanderWalde NA, Salloum RG, Liu TL, Hornbrook MC, O'Keeffe Rosetti MC, Ritzwoller DP, Fishman PA, Elston Lafata J, Khandani AH, Chera BS. Positron emission tomography and stage migration in head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014 Jul.140(7):654-661. Pubmedid: 24875939. Pmcid: PMC6000724.
- Khandani AH, Rathmell WK, Wallen EM, Ivanovic M. PET/CT with (124)I-cG250: great potential and some open questions. AJR Am J Roentgenol. 2014 Aug.203(2):261-262. Pubmedid: 25055257.
- Khandani AH, Cowey CL, Moore DT, Gohil H, Rathmell WK. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib. Nucl Med Commun. 2012 Sep.33(9):967-973. Pubmedid: 22714005.
- Fried D, Lawrence M, Khandani AH, Rosenman J, Cullip T, Chera BS. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?. Int J Radiat Oncol Biol Phys. 2012 Nov.84(3):748-754. Pubmedid: 22414285.
- Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. J Clin Oncol. 2012 Nov.30(32):3953-3959. Pubmedid: 23045594.
- Fried D, Khandani A, Shores C, Weissler M, Hayes N, Hackman T, Rosenman J, Chera BS. Matched cohort analysis of the effect of pretreatment positron emission tomography on clinical outcomes of patients with head and neck cancer treated with definitive chemoradiotherapy. Head Neck. 2012 Mar.34(3):412-417. Pubmedid: 21853498.
- Khandani AH, Rathmell WK. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Semin Nucl Med. 2012 Jul.42(4):221-230. Pubmedid: 22681671. Pmcid: PMC9205609.
- Mirpour S, Meteesatien P, Khandani AH. Does hyperglycemia affect the diagnostic value of 18F-FDG PET/CT?. Rev Esp Med Nucl Imagen Mol. 2012 Aug.31(2):71-77. Pubmedid: 22088805.
- Xie L, Saynak M, Veeramachaneni NK, Fried DV, Jagtap MR, Chiu WK, Higginson DS, Lawrence MV, Khandani AH, Qaqish BF, Chen RC, Marks LB. Non-small cell lung cancer: prognostic importance of positive FDG PET findings in the mediastinum for patients with N0-N1 disease at pathologic analysis. Radiology. 2011 Oct.261(1):226-234. Pubmedid: 21813742.
- Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O'Neil BH. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010 Sep.21(9):1377-1384. Pubmedid: 20691606. Pmcid: PMC2945527.
- Khandani AH, Dunphy CH, Meteesatien P, Dufault DL, Ivanovic M, Shea TC. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2009 Aug.30(8):594-601. Pubmedid: 19536037.
- Khandani AH, Funkhouser WK, Feins R, Socinski MA. Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancer. Ann Nucl Med. 2009 Aug.23(6):595-597. Pubmedid: 19437096.
- Khandani AH, Calvo BF, O'Neil BH, Jorgenson J, Mauro MA. A pilot study of early 18F-FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. AJR Am J Roentgenol. 2007 Nov.189(5):1199-1202. Pubmedid: 17954661.
- Khandani AH, Fielding JR. PET in management of small pulmonary nodules. Radiology. 2007 Mar.242(3):948-949. Pubmedid: 17325080.
- Khandani AH, Whitney KD, Keller SM, Isasi CR, Donald Blaufox M. Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer. Nucl Med Commun. 2007 Mar.28(3):173-177. Pubmedid: 17264775.
- Stinchcombe TE, Walters R, Khandani AH, Socinski MA. Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer. J Clin Oncol. 2007 Apr.25(12):1621-1623. Pubmedid: 17443003.
- Stinchcombe TE, Socinski MA, Gangarosa LM, Khandani AH. Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan. J Clin Oncol. 2006 Oct.24(30):4939-4940. Pubmedid: 17050879.
- Khandani AH, Detterbeck FC. Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less. J Thorac Cardiovasc Surg. 2006 Jul.132(1):214-215. Pubmedid: 16798357.
- Biehn SE, Kirk D, Rivera MP, Martinez AE, Khandani AH, Orlowski RZ. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol. 2006 Dec.24(4):234-237. Pubmedid: 16948177.
- Khandani AH, Isasi CR, Donald Blaufox M. Intra-individual variability of cardiac uptake on serial whole-body 18F-FDG PET. Nucl Med Commun. 2005 Sep.26(9):787-791. Pubmedid: 16096582.
- Khandani AH, Wahl RL. Applications of PET in liver imaging. Radiol Clin North Am. 2005 Sep.43(5):849-60, vii. Pubmedid: 16098343.
- Khandani AH, Semelka RC. Can the relation between gadopentetate dimeglumine and FDG uptake in colorectal liver metastases be used clinically?. Radiology. 2005 Oct.237(1):1-2. Pubmedid: 16183917.
- Detterbeck FC, Vansteenkiste JF, Morris DE, Dooms CA, Khandani AH, Socinski MA. Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer. Chest. 2004 Nov.126(5):1656-1666. Pubmedid: 15539740.
- Khandani A, Schicha H. [Two-step radioiodine therapy in benign thyroid diseases during a single hospital visit--observations on 100 patients]. Nuklearmedizin. 1999 Jan.38(5):140-143. Pubmedid: 10488480.
-
Patient Comments
0 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
Learn more about our patient comments
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments